T
Timothy M. Uyeki
Researcher at Centers for Disease Control and Prevention
Publications - 338
Citations - 47420
Timothy M. Uyeki is an academic researcher from Centers for Disease Control and Prevention. The author has contributed to research in topics: Influenza A virus subtype H5N1 & Influenza A virus. The author has an hindex of 86, co-authored 309 publications receiving 42818 citations. Previous affiliations of Timothy M. Uyeki include National Center for Immunization and Respiratory Diseases & University of California, San Francisco.
Papers
More filters
Journal ArticleDOI
Rapid influenza diagnostic test use and antiviral prescriptions in outpatient settings pre- and post-2009 H1N1 pandemic.
Laurina O. Williams,Nancy Kupka,Stephen Schmaltz,Stacey C. Barrett,Timothy M. Uyeki,Daniel B. Jernigan +5 more
TL;DR: Clinicians in outpatient facilities often relied on RIDT findings to aid in making antiviral treatment decisions; however their treatment practices were not always consistent with CDC guidelines.
Journal ArticleDOI
2009 H1N1 Virus Transmission and Outbreaks
TL;DR: The emergence of 2009 pandemic influenza A (H1N1) virus prompted early questions about how the virus was spreading and how easily it was transmitted, along with uncertainty about disease severity, clinical complications and risk factors for severe disease, and the effectiveness of antiviral treatment and control measures.
Journal ArticleDOI
Long-term Management of Panuveitis and Iris Heterochromia in an Ebola Survivor
Jessica G. Shantha,Ian Crozier,Jay B. Varkey,Colleen S. Kraft,G. Marshall Lyon,Aneesh K. Mehta,Renee Donahue Carlson,Charles E. Hill,Gokul Kumar,Matthew R. Debiec,Purnima Patel,Timothy W. Olsen,Robert B. Nussenblatt,Daniel F. Martin,Ute Ströher,Timothy M. Uyeki,Bruce S. Ribner,Justine R. Smith,Steven Yeh +18 more
Journal ArticleDOI
Serum Sickness-Like Reaction Associated with Inactivated Influenza Vaccination among Thai Health Care Personnel: Risk Factors and Outcomes
TL;DR: Fourteen of 495 Thai health care personnel identified as having a serum sickness-like reaction in 2008 after receipt of inactivated influenza vaccine manufactured in Thailand experienced fever, myalgia, centrifugal arthralgias, and injection site erythema.
Journal ArticleDOI
Cost-Effectiveness of Oseltamivir Treatment for Children with Uncomplicated Seasonal Influenza
TL;DR: Empiric oseltamivir treatment of seasonal influenza is associated with favorable cost-effectiveness ratios, particularly in children aged 1 to <12 years, but ratios are highly dependent on the prevalence of oselmivir resistance among circulating influenza viruses.